Roche receives positive CHMP opinion for Gavreto
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
Klifovet’s client base comprises the world’s top animal health and nutrition companies as well as many promising startups
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
Between 30-40 per cent of Covid-19 patients are either obese or diabetic
It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
Packaged junk food which is a major component of unhealthy diets is responsible for more deaths worldwide than any other risk factor
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
Subscribe To Our Newsletter & Stay Updated